The manufacturing method provided by the present invention is a method for manufacturing core-shell particles that includes core particles and a shell, the constituent metal elements of the foregoing being different from each other. In the present invention, a quinone-containing core particle dispersion containing at least core particles consisting of a first metal, hydroquinone (HQ), benzoquinone (BQ), and a second metal compound including a second metal element for making up the shell is prepared, and a reduction treatment is performed on the quinone-containing core particle dispersion, through addition of a reducing agent, to form a shell including the second metal element as a main constituent element, on the surface of the core particles. A mass ratio: HQ/BQ ratio of added hydroquinone (HQ) and benzoquinone (BQ) is 0.1 to 120.

Described herein is a powder coating that includes a plurality of particles. The plurality of particles includes amorphous polyester and iron oxide pigment, wherein the plurality of particles have a size of from 5 microns to 250 microns, and wherein the plurality of particles each have a circularity of from about 0.93 to about 0.999. A method of manufacturing the particles is also disclosed.

Nano- to microscale liquid coacervate particles are provided. The liquid coacervate particles are produced by a process including stimulating a population of liquid droplets containing one or a mixture of components to induce a phase separation point of a first component, and maintaining stimulation at the phase separation point to form a coacervate domain of the first component within each of the droplets to form the liquid coacervate particles. The self-assembled nano, meso, micro and macro liquid coacervate particles and related coated substrates can have utility in drug delivery, bioanalytical systems, controlled cell culture, tissue engineering, biomanufacturing and drug discovery.

Nano- to microscale liquid coacervate particles are provided. The liquid coacervate particles are produced by a process including stimulating a population of liquid droplets containing one or a mixture of components to induce a phase separation point of a first component, and maintaining stimulation at the phase separation point to form a coacervate domain of the first component within each of the droplets to form the liquid coacervate particles. The self-assembled nano, meso, micro and macro liquid coacervate particles and related coated substrates can have utility in drug delivery, bioanalytical systems, controlled cell culture, tissue engineering, biomanufacturing and drug discovery.

The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months.

In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.

The present invention relates to extended release microparticles comprising a drug, and a preparation method therefor, and when the extended release microparticles comprising a drug are administered in order to replace conventional drugs that should be administered daily or monthly, the drug administration effect can be continuously maintained for one week to three months.

In addition, the drug administration effect is maintained for a long time and, simultaneously, microparticles are prepared so as to have the average diameter of a fixed micro-size, and thus an effective drug concentration can be constantly maintained by controlling the release of the drug from the microparticles, and a foreign body sensation and pain can be reduced during drug administration since microparticles having a uniform size are included during application as an injectable drug.

A method for forming a lipid membrane vesicle includes: filling a chamber with a first aqueous solution by introducing it to a liquid flow path facing a microreactor chip hydrophobic layer main surface; forming a first lipid monolayer membrane in an opening part of the chamber filled with the solution; forming a second lipid monolayer membrane on a layer interface of the organic solvent formed on the main surface of the hydrophobic layer with a second aqueous solution by introducing the solution to the liquid flow path; allowing a first aqueous solution form in the chamber to alter to a spherical droplet covered with the first lipid monolayer membrane; and forming a lipid membrane vesicle by moving the droplet to a position of the second lipid monolayer membrane by applying a physical action, and by zipping the first lipid monolayer membrane covering the droplet and the second lipid monolayer membrane.

A method for forming a lipid membrane vesicle includes: filling a chamber with a first aqueous solution by introducing it to a liquid flow path facing a microreactor chip hydrophobic layer main surface; forming a first lipid monolayer membrane in an opening part of the chamber filled with the solution; forming a second lipid monolayer membrane on a layer interface of the organic solvent formed on the main surface of the hydrophobic layer with a second aqueous solution by introducing the solution to the liquid flow path; allowing a first aqueous solution form in the chamber to alter to a spherical droplet covered with the first lipid monolayer membrane; and forming a lipid membrane vesicle by moving the droplet to a position of the second lipid monolayer membrane by applying a physical action, and by zipping the first lipid monolayer membrane covering the droplet and the second lipid monolayer membrane.

An anti-clogging microfluidic multichannel device comprising a first mixing chamber comprising a first and a second end, wherein the first end comprises at least one inlet connected in fluid communication with the first mixing chamber, and at least one first capillary element comprising a first and a second end, wherein the first end of the at least one first capillary element is connected in fluid communication with the second end of the first mixing chamber, at least one septum located within the at least one first capillary element, which divides the cross section of the at least one first capillary element in a plurality of channels, wherein the at least one first capillary element comprises a reduction of section along its longitudinal axis between a section of the at least one first capillary element and the second end of the at least one first capillary element. It is also described a microfluidics system and a method of production of emulsions using said microfluidics system.

An anti-clogging microfluidic multichannel device comprising a first mixing chamber comprising a first and a second end, wherein the first end comprises at least one inlet connected in fluid communication with the first mixing chamber, and at least one first capillary element comprising a first and a second end, wherein the first end of the at least one first capillary element is connected in fluid communication with the second end of the first mixing chamber, at least one septum located within the at least one first capillary element, which divides the cross section of the at least one first capillary element in a plurality of channels, wherein the at least one first capillary element comprises a reduction of section along its longitudinal axis between a section of the at least one first capillary element and the second end of the at least one first capillary element. It is also described a microfluidics system and a method of production of emulsions using said microfluidics system.